A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens

• Published in: Mayo Clinic proceedings. Innovations, quality & outcomes quality & outcomes, 2019-03, Vol.3 (1), p.14-22
• Main Authors: Jimenez, Rafael E., Atwell, Thomas D., Sicotte, Hughes, Eckloff, Bruce, Wang, Liguo, Barman, Poulami, Sinnwell, Jason P., Eiken, Patrick W., McMenomy, Brendan P., Tan, Winston, Wang, Liewei, Carlson, Rachel E., Kohli, Manish
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2542-4548; 2542-4548
• DOI: 10.1016/j.mayocpiqo.2018.12.005

To determine histopathologic, exome, and transcriptome nucleic acid material yield from prospectively collected metastatic tissue biopsy specimens in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients with mCRPC initiating abiraterone acetate therapy underwent 2 serial metastatic site core needle biopsies after study activation on May 17, 2013. Multiple cores were obtained, and from each core, 1- to 2-mm segments were separated and formalin fixed for histopathologic examination. Tumor purity was determined for DNA and RNA from the rest of the biopsy specimen. RNA quality was assessed by calculation of an RNA integrity number and a DV200 score. A total of 89 patients underwent 172 uniformly processed core needle biopsies (89 on visit 1 and 83 on visit 2) between May 30, 2013, and September 10, 2015. Metastatic sites biopsied included bone (131), lymph nodes (31), liver (5), lung (3), and pelvic soft tissues (2). Of the 172 biopsy specimens, 85 (49%) had at least one of the multiple cores positive for tumor on histopathologic examination (53 of 88 [60%] from visit 1 and 32 of 83 [39%] from visit 2; P=.006). Metastatic carcinoma was observed in 50 of 130 bone lesion specimens (38%), compared to 35 of 41 nonbone specimens (85%) (P